Goulet Stephanie, Bihl Michel P, Gambazzi Franco, Tamm Michael, Roth Michael
Department of Research, Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
J Cell Physiol. 2007 Jan;210(1):167-76. doi: 10.1002/jcp.20836.
Asthma and chronic obstructive pulmonary disease (COPD) are characterized by chronic airway inflammation and major structural lung tissue changes including increased extracellular matrix (ECM) deposition. Inhaled corticosteroids and long-acting beta(2)-agonists (LABA) are the basic treatment for both diseases, but their effect on airway remodeling remains unclear. In this study, we investigated the effect of corticosteroids and LABA, alone or in combination, on total ECM and collagen deposition, gene expression, cell proliferation, and IL-6, IL-8, and TGF-beta(1) levels by primary human lung fibroblasts. In our model, fibroblasts in 0.3% albumin represented a non-inflammatory condition and stimulation with 5% FCS and/or TGF-beta(1) mimicked an inflammatory environment with activation of tissue repair. FCS (5%) increased total ECM, collagen deposition, cell proliferation, and IL-6, IL-8, and TGF-beta(1) levels. In 0.3% albumin, corticosteroids reduced total ECM and collagen deposition, involving the glucocorticoid receptor (GR) and downregulation of collagen, heat shock protein 47 (Hsp47), and Fli1 mRNA expression. In 5% FCS, corticosteroids increased ECM deposition, involving upregulation of COL4A1 and CTGF mRNA expression. LABA reduced total ECM and collagen deposition under all conditions partly via the beta(2)-adrenergic receptor. In combination, the drugs had an additive effect in the presence or absence of TGF-beta(1) further decreasing ECM deposition in 0.3% albumin whereas counteracting each other in 5% FCS. These data suggest that the effect of corticosteroids, but not of LABA, on ECM deposition by fibroblasts is altered by serum. These findings imply that as soon as airway inflammation is resolved, long-term treatment with combined drugs may beneficially reduce pathological tissue remodeling.
哮喘和慢性阻塞性肺疾病(COPD)的特征是慢性气道炎症以及肺组织的主要结构变化,包括细胞外基质(ECM)沉积增加。吸入性糖皮质激素和长效β2受体激动剂(LABA)是这两种疾病的基础治疗药物,但其对气道重塑的影响尚不清楚。在本研究中,我们调查了糖皮质激素和LABA单独或联合使用对原代人肺成纤维细胞的总ECM和胶原蛋白沉积、基因表达、细胞增殖以及白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和转化生长因子-β1(TGF-β1)水平的影响。在我们的模型中,0.3%白蛋白中的成纤维细胞代表非炎症状态,用5%胎牛血清(FCS)和/或TGF-β1刺激可模拟炎症环境并激活组织修复。5% FCS可增加总ECM、胶原蛋白沉积、细胞增殖以及IL-6、IL-8和TGF-β1水平。在0.3%白蛋白中,糖皮质激素可减少总ECM和胶原蛋白沉积,这涉及糖皮质激素受体(GR)以及胶原蛋白、热休克蛋白47(Hsp47)和Fli1 mRNA表达的下调。在5% FCS中,糖皮质激素可增加ECM沉积,这涉及COL4A1和结缔组织生长因子(CTGF)mRNA表达的上调。LABA在所有条件下均可部分通过β2肾上腺素能受体减少总ECM和胶原蛋白沉积。联合使用时,无论是否存在TGF-β1,药物均具有相加作用,在0.3%白蛋白中进一步减少ECM沉积,而在5% FCS中则相互抵消。这些数据表明,血清可改变糖皮质激素而非LABA对成纤维细胞ECM沉积的影响。这些发现意味着,一旦气道炎症消退,联合药物的长期治疗可能会有益地减少病理性组织重塑。